The Europe Influenza market is growing at a significant CAGR due to increase in geriatric population. Increase in vaccination awareness, rising investment by companies in research and development activities, and increasing number of immunization programs organized by the government are the major factors fuelling the growth of Europe influenza market over the forecast period. The major market players have great pipeline products, Initiatives by government bodies such as WHO to ECDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of Europe influenza market over the forecast period. However, lack of required funding, limited opportunities for the production of vaccines, and stringent regulatory policies for new product approvals might hamper the growth of Europe Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increasing prices of Influenza diagnostic kits, and difficulties in the storage of inventory also hinder the Europe influenza market.A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-europe-influenza-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
The Europe influenza market is segmented on the basis of product type, distribution channel, and end user
Based on drug class, Europe influenza market is segmented into the following:
Anti-viral drugs
Zanamivir
Oseltamivir
Amantadine
Rimantadine
Others
Interferons
Vaccines
Trivalent
Quadrivalent
Based on route of administration, Europe influenza market is segmented into the following:
Oral
Parenteral
Others
Based on end-user, Europe influenza market is segmented into the following:
Hospital pharmacies
Retail pharmacies
Others
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-europe-influenza-market/#ulp-c654SbFYO64MsOhu[/URL]
Several international players in Europe are actively involved in the development of vaccines and drugs for influenza treatment to increase its market share. Vaccines are majorly preferred for the influenza treatment which is key revenue contributor for the growth of Europe Influenza market share. Launching of new products, technological innovations, and approvals from European Medical Agency for various drugs might fuel the growth of Europe Influenza market. For instance, in July 2016, Sanofi Pasteur MSD announced the approval of the latest addition to its family of influenza vaccines in the UK. Similarly, during 2009, three vaccines Celvapan, Pandemrix, and Focetria were authorized as the mock-up vaccines and converted into the pandemic-influenza vaccines after the identification of A/H1N11 flu strain.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-europe-influenza-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in Europe influenza market are AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline Plc. (U.K.), Novartis AG (Switzerland), Sanofi (France), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc. (U.S.), and Abbott Laboratories Inc. (U.S.) to name a few.